Trials / Terminated
TerminatedNCT01108705
Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether brivanib is an effective treatment for liver cancer in Asian patients who have failed or could not tolerate sorafenib therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brivanib | Tablets, Oral, 800 mg, once daily, until disease progression or toxicity |
| DRUG | Placebo | Tablets, Oral, 0mg, once daily, until disease progression or toxicity |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2010-04-22
- Last updated
- 2015-10-12
Locations
32 sites across 4 countries: China, Singapore, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01108705. Inclusion in this directory is not an endorsement.